Does the media prefer ALVO or TRDA?

In the previous week, Entrada Therapeutics had 6 more articles in the media than Alvotech. MarketBeat recorded 13 mentions for Entrada Therapeutics and 7 mentions for Alvotech. Alvotech's average media sentiment score of 1.25 beat Entrada Therapeutics' score of 0.44 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BIOA or TRDA?

In the previous week, BioAge Labs had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 14 mentions for BioAge Labs and 13 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.44 beat BioAge Labs' score of 0.20 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Entrada Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TRDA or PHAR?

In the previous week, Pharming Group had 12 more articles in the media than Entrada Therapeutics. MarketBeat recorded 25 mentions for Pharming Group and 13 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.44 beat Pharming Group's score of -0.11 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 2 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer PURR or TRDA?

In the previous week, Entrada Therapeutics had 10 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 13 mentions for Entrada Therapeutics and 3 mentions for Hyperliquid Strategies. Entrada Therapeutics' average media sentiment score of 0.44 beat Hyperliquid Strategies' score of 0.28 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SANA or TRDA?

In the previous week, Entrada Therapeutics had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 13 mentions for Entrada Therapeutics and 3 mentions for Sana Biotechnology. Entrada Therapeutics' average media sentiment score of 0.44 beat Sana Biotechnology's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Entrada Therapeutics (TRDA) Competitors

$7.24 -0.02 (-0.28%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$7.45 +0.21 (+2.94%)

As of 08:31 AM Eastern

Compare

TRDA vs. ALVO, BIOA, PHAR, PURR, and SANA

Should you buy Entrada Therapeutics stock or one of its competitors? MarketBeat compares Entrada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entrada Therapeutics include Alvotech (ALVO), BioAge Labs (BIOA), Pharming Group (PHAR), Hyperliquid Strategies (PURR), and Sana Biotechnology (SANA).

How does Entrada Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Alvotech presently has a consensus target price of $7.60, indicating a potential upside of 97.92%. Entrada Therapeutics has a consensus target price of $17.50, indicating a potential upside of 141.71%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alvotech has higher revenue and earnings than Entrada Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.97	$27.92M	-$0.25	N/A
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A

In the previous week, Entrada Therapeutics had 6 more articles in the media than Alvotech. MarketBeat recorded 13 mentions for Entrada Therapeutics and 7 mentions for Alvotech. Alvotech's average media sentiment score of 1.25 beat Entrada Therapeutics' score of 0.44 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alvotech has a net margin of -14.36% compared to Entrada Therapeutics' net margin of -2,895.05%. Alvotech's return on equity of -11.92% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Alvotech has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

86.4% of Entrada Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Alvotech and Entrada Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, BioAge Labs had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 14 mentions for BioAge Labs and 13 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.44 beat BioAge Labs' score of 0.20 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Entrada Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioAge Labs has higher earnings, but lower revenue than Entrada Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	48.26	-$80.61M	-$2.40	N/A
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A

BioAge Labs has a net margin of -871.75% compared to Entrada Therapeutics' net margin of -2,895.05%. BioAge Labs' return on equity of -29.40% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

BioAge Labs currently has a consensus price target of $36.57, indicating a potential upside of 226.53%. Entrada Therapeutics has a consensus price target of $17.50, indicating a potential upside of 141.71%. Given BioAge Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe BioAge Labs is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

BioAge Labs has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

86.4% of Entrada Therapeutics shares are held by institutional investors. 17.5% of BioAge Labs shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioAge Labs beats Entrada Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Pharming Group?

Entrada Therapeutics (NASDAQ:TRDA) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Pharming Group has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A
Pharming Group	$376.13M	1.93	$2.85M	$0.12	85.50

Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Entrada Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 141.71%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 276.87%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Pharming Group had 12 more articles in the media than Entrada Therapeutics. MarketBeat recorded 25 mentions for Pharming Group and 13 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.44 beat Pharming Group's score of -0.11 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	2 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Pharming Group has a net margin of 2.51% compared to Entrada Therapeutics' net margin of -2,895.05%. Pharming Group's return on equity of 3.40% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Pharming Group	2.51%	3.40%	1.90%

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pharming Group beats Entrada Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Entrada Therapeutics (NASDAQ:TRDA) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Hyperliquid Strategies has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	983.70	-$16.01M	-$7.37	N/A
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hyperliquid Strategies has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Hyperliquid Strategies presently has a consensus target price of $12.72, suggesting a potential upside of 86.74%. Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 141.71%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Hyperliquid Strategies has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 10 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 13 mentions for Entrada Therapeutics and 3 mentions for Hyperliquid Strategies. Entrada Therapeutics' average media sentiment score of 0.44 beat Hyperliquid Strategies' score of 0.28 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Entrada Therapeutics beats Hyperliquid Strategies on 9 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sana Biotechnology has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Sana Biotechnology currently has a consensus price target of $9.50, suggesting a potential upside of 179.41%. Entrada Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 141.71%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Entrada Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A

Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 13 mentions for Entrada Therapeutics and 3 mentions for Sana Biotechnology. Entrada Therapeutics' average media sentiment score of 0.44 beat Sana Biotechnology's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Entrada Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$281.84M	$3.52B	$6.83B	$12.77B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-1.81	7.32	279.15	25.53
Price / Sales	11.06	1,269.15	587.36	92.31
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	0.90	17.36	13.06	6.11
Net Income	-$143.75M	-$12.52M	$3.48B	$347.58M
7 Day Performance	10.53%	3.64%	3.38%	4.91%
1 Month Performance	-6.22%	-5.38%	-2.81%	-2.06%
1 Year Performance	24.19%	49.44%	73.07%	21.03%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	3.2275 of 5 stars	$7.24 -0.3%	$17.50 +141.7%	+22.3%	$281.84M	$25.42M	N/A	110	News Coverage Earnings Report Insider Trade Gap Down
ALVO Alvotech	3.6485 of 5 stars	$3.10 +0.6%	$7.60 +145.2%	-56.7%	$929.56M	$588.90M	N/A	1,460
BIOA BioAge Labs	3.2004 of 5 stars	$21.92 +5.0%	$43.50 +98.4%	+153.4%	$928.17M	$8.99M	N/A	N/A	Analyst Forecast
PHAR Pharming Group	3.5083 of 5 stars	$12.86 -1.2%	$38.33 +198.1%	-16.2%	$921.04M	$376.13M	80.38	280	Earnings Report Analyst Forecast Analyst Revision Gap Up
PURR Hyperliquid Strategies	2.0717 of 5 stars	$6.17 -2.7%	$12.72 +106.1%	N/A	$915.80M	$1M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ALVO, BIOA, PHAR, PURR, and SANA

How does Entrada Therapeutics compare to Alvotech?

Summary

How does Entrada Therapeutics compare to BioAge Labs?

Summary

How does Entrada Therapeutics compare to Pharming Group?

Summary

How does Entrada Therapeutics compare to Hyperliquid Strategies?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ALVO, BIOA, PHAR, PURR, and SANA

How does Entrada Therapeutics compare to Alvotech?

Do analysts rate ALVO or TRDA?

Which has preferable earnings & valuation, ALVO or TRDA?

Does the media prefer ALVO or TRDA?

Is ALVO or TRDA more profitable?

Which has more volatility and risk, ALVO or TRDA?

Do insiders and institutionals believe in ALVO or TRDA?

Summary

How does Entrada Therapeutics compare to BioAge Labs?

Does the media prefer BIOA or TRDA?

Which has stronger valuation & earnings, BIOA or TRDA?

Is BIOA or TRDA more profitable?

Do analysts rate BIOA or TRDA?

Which has more risk & volatility, BIOA or TRDA?

Do institutionals & insiders believe in BIOA or TRDA?

Summary

How does Entrada Therapeutics compare to Pharming Group?

Which has preferable earnings and valuation, TRDA or PHAR?

Which has more risk and volatility, TRDA or PHAR?

Do analysts rate TRDA or PHAR?

Does the media refer more to TRDA or PHAR?

Is TRDA or PHAR more profitable?

Do institutionals and insiders believe in TRDA or PHAR?

Summary

How does Entrada Therapeutics compare to Hyperliquid Strategies?

Which has higher earnings & valuation, PURR or TRDA?

Do institutionals & insiders have more ownership in PURR or TRDA?

Is PURR or TRDA more profitable?

Do analysts prefer PURR or TRDA?

Which has more risk and volatility, PURR or TRDA?

Does the media prefer PURR or TRDA?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Do institutionals and insiders hold more shares of SANA or TRDA?

Is SANA or TRDA more profitable?

Do analysts prefer SANA or TRDA?

Which has preferable valuation & earnings, SANA or TRDA?

Which has more volatility and risk, SANA or TRDA?

Does the media prefer SANA or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools